Current opinion in HIV and AIDSHumansVirus LatencyHIV InfectionsHIV-1Anti-HIV Agents
Latency-reversing agents: where are we now?
Maryam Bendoumou, Carine Van Lint
Published: 202610.1097/COH.0000000000000993
Abstract
PURPOSE OF REVIEW: Despite effective antiretroviral therapy (ART), HIV-1 persists in latently infected cells that evade host immunity and can resume viral production upon treatment interruption. To address this challenge, the "shock and kill" strateg…
Preview only. Read the full abstract at the source